

Freedom of Information request 389-23

Request

1. Does your trust provide SACT (systemic anti-cancer therapy) treatments for endometrial cancer? If not, which other trust do you refer endometrial cancer patients to for SACT treatments?
2. How many patients were treated for endometrial cancer in the past 6 months with the following treatments:
 - Dostarlimab
 - Hormone therapy (Progesterone or Letrozole)
 - Pembrolizumab monotherapy
 - Pembrolizumab in combination with Lenvatinib
 - Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)
 - Any other SACT
3. How many endometrial cancer patients received the following therapies as 1st Line treatment in the past 6 months:
 - Hormone therapy (Progesterone or Letrozole)
 - Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)
 - Any other SACT
4. Of the patients treated for endometrial cancer in the past 6 months with any SACT regimen, how many patients had high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR)?
5. Does your trust participate in any clinical trials for the treatment of endometrial cancer? If so, can you please provide the name of each trial and the number of patients taking part.

Response

1. NHS Borders does provide Systemic Anti-Cancer Therapy (SACT) treatments for Endometrial Cancer.
2. The number of patients treated for Endometrial Cancer in the past 6 months is:

• Dostarlimab	0
• Hormone therapy (Progesterone or Letrozole)	<5
• Pembrolizumab monotherapy	0
• Pembrolizumab in combination with Lenvatinib	0
• Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide)	<5
• Any other SACT	0

3. The number of Endometrial Cancer patients receiving the following therapies as 1st Line treatment in the past 6 months is:
 - Hormone therapy (Progesterone or Letrozole) <5
 - Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) <5
 - Any other SACT 0
4. Of the patients treated for Endometrial Cancer in the past 6 months with any SACT regimen, <5 patients had high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR).
5. NHS Borders does not participate in any clinical trials for the treatment of Endometrial Cancer.

Please note that as NHS Borders is such a small Board the number of relevant patients is very small, and to provide further details of these could allow individuals to be identified and we would be in breach of the Data Protection Act 2018. We are therefore withholding all other data under Section 38(2)(ii) of the Freedom of Information (Scotland) Act 2002. This is also in accordance with the Code of Practice for Official Statistics any number that is less than five, actual numbers and potentially identifiable information is withheld to help maintain patient confidentiality due to potential risk of disclosure. Further information is available in the [ISD Statistical Disclosure Control Protocol](#).

If you are not satisfied with the way your request has been handled or the decision given, you may ask NHS Borders to review its actions and the decision. If you would like to request a review please apply in writing to, Freedom of Information Review, NHS Borders, Room 2EC3, Education Centre, Borders General Hospital, Melrose, TD6 9BS or foi.enquiries@borders.scot.nhs.uk.

The request for a review should include your name and address for correspondence, the request for information to which the request relates and the issue which you wish to be reviewed. Please state the reference number **389-23** on this request. Your request should be made within 40 working days from receipt of this letter.

If following this review, you remain dissatisfied with the outcome, you may appeal to the Scottish Information Commissioner and request an investigation of your complaint. Your request to the Scottish Information Commissioner should be in writing (or other permanent form), stating your name and an address for correspondence. You should provide the details of the request and your reasons for dissatisfaction with both the original response by NHS Borders and your reasons for dissatisfaction with the outcome of the internal review. Your application for an investigation by the Scottish Information Commissioner must be made within six months of your receipt of the response with which you are dissatisfied. The address for the Office of the Scottish Information Commissioner is, Office of the Scottish Information Commissioner, Kinburn Castle, Doubledykes Road, St Andrews, Fife.